138 results about "Long non-coding RNA" patented technology

A multi-gene-based assay for analysis of the following: (a) oncogene expression; (b) DNA methylation of tumor suppressor genes; (c) non-coding RNA expression (microRNA profiling); and (d) long non-coding RNA expression in cancer samples is disclosed. The assay method and device for conducting the assay are applicable to diagnosis, prognosis, and treatment of various cancers such as lung, breast, colorectal, prostate, liver, bladder; kidney, cervix, pancreatic, gastric, brain, oral, endometrium, and ovary. The assay methods allow avoidance of surgery to remove cancerous tissue.

The invention provides a long non-coding RNA and an application thereof. The long non-coding RNA has a sequence represented by SEQ ID No.1. The invention also provides a purpose of the long non-coding RNA as a tumor marker, and probes and primers used for detecting the long non-coding RNA. The invention also provides an inhibitor of the long non-coding RNA. The inhibitor assists in inhibiting the expression of the long non-coding RNA and tumor cell proliferation. The invention further provides a medicine composition comprising the inhibitor.

The invention discloses an in situ hybridization probe, a reagent and an application of long non-coding RNA LOC401317. The long non-coding RNA LOC401317 can be used for preparing a prognosis preparation for a patient with nasopharyngeal carcinoma, and particularly a kit for predicting prognosis of the patient with the nasopharyngeal carcinoma employing an in situ hybridization detection method is prepared. A research proves that expression of the LOC401317 in a nasopharyngeal carcinoma tissue is lowered, and the patient with the nasopharyngeal carcinoma in low-expression LOC401317 is worse than the patient with the nasopharyngeal carcinoma in high-expression LOC401317 in prognosis, therefore, expression of the LOC401317 is applied to prognosis prediction of the patient with nasopharyngeal carcinoma; a powerful molecular biology basis can be provided for prognosis of the patient with the nasopharyngeal carcinoma; and the long non-coding RNA LOC401317 has profound clinical significance and important popularization and application prospects.

The invention relates to a long non-coding RNA and application thereof. According to the sequence of the long non-coding RNA, a specific real-time quantitative Polymerase Chain Reaction (PCR) primer and a probe are designed and synthesized, and a preparation used for EC auxiliary diagnosis or curative effect prediction is prepared. With the real-time quantitative PCR preparation, the expression level of the long non-coding RNA in an EC clinical case specimen is detected, and the expression of the long non-coding RNA in the EC is obviously lowered. The invention aims to prepare a preparation used for EC auxiliary diagnosis, or curative effect prediction, or prognosis determination.

The invention provides long noncoding RNA (ribonucleic acid) CLMAT1 related with colorectal liver metastasis and application of the long noncoding RNA CLAMT1. The long noncoding RNA CLAMT1 is positioned at a 14th chromosome chr14: 101379770-101381326, hg19; the gene sequence length is 1557bp. Compared with normal intestinal tissues, intestinal tissues with the intestinal cancer has high expression of CLAMT1 which is positively correlated with liver metastases of colorectal cancer; in addition, bad prognosis of patients also indirectly prompts that the liver metastasis probability of the patients is relatively high.

The invention provides a long non-coding RNA (long non-coding RNA, 1ncRNA)-incRNA-HN3 sequence relevant to human melanoma cells, and an RNA interference (RNA interference, RNAi) target spot sequence, a short-hairpin RNA (short-hairpin RNA, shRNA) sequence, an shRNA coded small molecule interference RNA (small interference RNA, siRNA), a coding shRNA coding strand and an anti-sense strand DNA sequence, coding shRNA recombinant plasmids of the long non-coding RNA sequence, and the invention relates to the applications of the long non-coding RNA sequence for preparing reagents for diagnosing melanoma diseases and drugs for treating the melanoma diseases.

The invention discloses a long non-coding RNA (lnc RNA-UN) of human melanoma cell specific expression, an RNA interfering target spot thereof, a short hairpin RNA (shRNA) of the RNA interfering target spot, a small interfering RNA (siRNA), a sense strand DNA and an antisense strand DNA of the coding short hairpin RNA and a recombinant plasmid of a transcription short hairpin RNA. Proved by experiments, the lnc RNA-UN is highly expressed in a melanoma tissue and not expressed in a peficancerous tissue and can be applied to preparing a reagent for diagnosing melanoma diseases. Proved by the experiments, the recombinant plasmid of the transcription short hairpin RNA expresses the shRNA and the siRNA in a melanoma cell and can obviously degrade the cell endogenous lncRNA-UN and restrain the malignant growth of the melanoma cell, thus the shRNA and the siRNA of the RNA interfering target spot of the lncRNA-UN and the recombinant plasmid of the transcription short hairpin RNA can be applied to medicaments for treating the melanoma diseases.

The invention relates to a gastric cancer associated molecular marker IncRNA (long non-coding RNA) HOTTIP (HOXA transcript at the distal tip), an application of the molecular marker in auxiliary diagnosis of gastric cancer as well as a gastric carcinogenesis predicting kit. According to a sequence of the IncRNA, specific real-time fluorescent quantitative PCR (polymerase chain reaction) primers are designed and synthesized, and a reagent for auxiliary diagnosis of gastric cancer is prepared. Real-time fluorescent quantitative PCR proves that HOTTIP has differential expression between gastric cancer tissue and normal tissue beside the gastric cancer tissue and has down-regulated expression in the gastric cancer tissue. The gastric cancer associated molecular marker IncRNA HOTTIP can be used for evaluation and diagnosis of gastric carcinogenesis, facilitates screening of individuals having high risks of the gastric cancer and guides making of reasonable monitoring, following, processing and treating schemes clinically.

The invention provides new and separated long non-coding RNA (Ribonucleic Acid). The long non-coding RNA has a sequence shown by SEQ ID No1. The invention further provides applications of the long non-coding RNA as a tumor marker, and a probe and a primer for detecting the long non-coding RNA. The invention further provides an inhibitor of the long non-coding RNA, wherein the inhibitor can inhibit the expression of the long non-coding RNA and tumor cell proliferation. The invention further provides a drug composition comprising the inhibitor.

The invention relates to a method for promoting myogenic differentiation of bovine skeletal muscle satellite cells. According to the method, myogenic differentiation of bovine skeletal muscle satellite cells is promoted by interfering lncRNA-HZ5 expression. The specific method comprises the steps as follows: siRNA of lncRNA-HZ5 is designed and synthesized according to an lncRNA-HZ5 base sequence, siRNA is used for transfection of the bovine skeletal muscle satellite cells, the expression level of lncRNA-HZ5 is lowered, and myogenic differentiation of the bovine skeletal muscle satellite cells is promoted, wherein the genome base sequence of lncRNA-HZ5 is shown in SQ1. The myogenic differentiation process of the bovine skeletal muscle satellite cells regulated by changing lncRNA-HZ5, enlightenment is provided for long non-coding RNA research of muscle development differentiation, and a new idea and reference are provided for clinical research, diagnosis and treatment of muscle development differentiation and damage repair.

The invention discloses a long non-coding RNA (lncRNA) MALAT-1, and application thereof as a prostatic cancer marker and application thereof to preparation of chips, preparations or kits for detection of prostatic cancer.

The invention belongs to the field of genetic engineering and in particular relates to an application of long non-coding RNA (lncRNA) DUXAP8 to prognosis of gastric cancers and target drug treatment. With up-regulation of IncRNA DUXAP8 in gastric cancer cells, prognosis of patients with IncRNA DUXAP8 with high expression level is relatively poor. Effects are exerted on invasion, migration, and the like of the gastric cancer cells by changing expression of IncRNA DUXAP8. Gastric cancer cell proliferation and apoptosis induction can be inhibited by knocking down IncRNA DUXAP8 expression.

This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.

The invention discloses an application method of serum Exosomes-derived long non-coding RNA (long no-coding RNA, LncRNA) PRKAG2-AS1, namely, the serum Exosomes-derived LncRNA PRKAG2-AS1 is used for preparing drugs for the screening and early diagnosis of high-risk population with gliomas or prognosis preparations for patients with gliomas. Through researching, a situation that RNA is extracted after Exosomes are separated from serums of patients with gliomas, then the RNA is subjected to reverse transcription and real-time fluorescent quantitative analysis, and the expression level of LncRNA PRKAG2-AS1 drops is verified. The specificity of the preparation disclosed by the invention and for the early diagnosis of gliomas can reach 85.7%, and the sensitivity reaches 88.2%. Through detecting the expression level of LncRNA PRKAG2-AS1 in serum Exosomes of patients with gliomas, the early and rapid noninvasive diagnosis on the patients with gliomas is implemented.

The invention provides application of LncRNA (long non-coding RNA) and a medicine using the same, and relates to the technical field of medical biology. The LncRNA provided by the invention has the nucleotide sequence shown as SEQ ID NO.1, and experiments find that the expression of the LncRNA is significantly decreased in cardiomyocytes suffering from cell death and heart tissues and the LncRNA has a protective effect on myocardial infarction and myocardial fibrosis, so that through overexpression of the LncRNA, the purposes of preventing and / or treating heart diseases can be achieved. The invention further provides the medicine comprising the LncRNA. The medicine can achieve the purposes of preventing and / or treating the heart diseases through the overexpression of the LncRNA; meanwhile,the medicine is obvious in therapeutic effect, wide in application range and friendly to using environment.

The invention belongs to the field of gene engineering, and in particular relates to application of Lincpint in preparation of T2DM prediction and targeted treatment drugs, down-regulation of the Lincpint in T2DM mice is relate to function injuries of pancreatic beta cells, the Lincpint of a low expression level may participate the pathogenesis of the T2DM, and by change of the expression of the Lincpint, the apoptosis of the pancreatic beta cells and synthesis and secretion of insulin can be influenced.

The invention discloses a triple network resource propagating method. The method is applied to a research process of an association relation between an environmental factor and a long non-coding RNA (Ribonucleic Acid) in bioinformatics. In combination with IncRNAs-miRNAs and miRNAs-EFs association network and resource transfer in the network, the invention provides an inference method based on a network to deduce the potential correlation between the IncRNAs and the EFs. Experimental analysis results show that, compared with other provided methods, the method can predict a reliable relation between the IncRNAs and the EFs. The results prove that the method predicts the biological significant correlation capability and helps people to understand a molecular process.

The invention relates to the technical field of biological information, and discloses a method and system for predicting the association between long non-coding RNA and protein, used for ensuring the prediction accuracy and reducing the experimental cost. The method comprises the following steps of: constructing a first subnet that lncRNA and protein are mutually associated, a second subnet that lncRNA and lncRNA are mutually associated, and a third subnet that protein and protein are mutually associated; combining the various subnets to construct a global heterogeneous network; determining at least two migration paths that any lncRNA and any protein are associated in the global heterogeneous network; connecting the first subnet with at least one of the second subnet and the third subnet in series by any migration path; calculating the HeteSim fractions of the various migration paths through a HeteSim algorithm; and performing construction and evaluation of a classification model used for predicting the association between non-coding RNA and protein according to the corresponding HeteSim fractions of the various migration paths between an lncRNA source end and a protein host end in the global heterogeneous network.

The application obtains a marker through clinical sample screening that can be used as a marker for the diagnosis of colorectal cancer, which is a long-chain non-coding RNA, that is, IncRNA. The sequence of the IncRNA is shown in SEQ ID NO: 1, and it is designed to inhibit The positive RNAi fragment SEQ ID NO: 4 and transfected cells show that the expression of the IncRNA can be reduced, the proliferation and migration of tumor cells can be significantly inhibited, and the apoptosis rate of tumor cells can be increased. It is a potential therapeutic agent.

The invention relates to a long non-coding RNA and application thereof. According to the sequence of the long non-coding RNA, a specific real-time quantitative Polymerase Chain Reaction (PCR) primer and a probe are designed and synthesized, and a preparation used for EC auxiliary diagnosis or curative effect prediction is prepared. With the real-time quantitative PCR preparation, the expression level of the long non-coding RNA in an EC clinical case specimen is detected, and the expression of the long non-coding RNA in the EC is lowered obviously. The invention aims to prepare a preparation used for EC auxiliary diagnosis, or curative effect prediction, or prognosis determination.

The invention discloses siRNA-203 for inhibiting expression of long-chain non-coding RNA SNHG6 and proliferation of hepatoma cells and application thereof. A positive-sense strand of the SiRNA-203 is as shown in SEQ ID NO.1, and an anti-sense strand of the SiRNA-203 is as shown in SEQ ID NO. 2. The siRNA-203 can effectively inhibit the expression of an SNHG6 gene with the down-regulation degree of 10 times, and can effectively inhibit the proliferation of the hepatoma cells and induce the apoptosis of the hepatoma cells. The SiRNA-203 can be further applied to studying functions of the SNHG6 gene and preparing a medicament for treating hepatoma.

The invention discloses application of long non coding RNA (lncRNA) and interfering RNA thereof to treatment on atherosclerosis. Through high-throughput sequencing on an aortic tissue of an atherosclerosis mouse model, the invention discovers that the expression of lncRNA molecules in normal and late atherosclerosis mice is obviously different; and meanwhile, the lncRNA molecules are highly expressed in the atherosclerosis tissue and the lncRNA molecules are named as lncRNA-AFIAR. The experiment proves that the lncRNA-AFIAR has the functions of enhancing proliferation of macrophages, inhibiting macrophage apoptosis and the like and participates in the process of promoting the progress of the atherosclerosis. The aims of inhibiting the proliferation of the macrophages and reducing plaque formation can be fulfilled by inhibiting the lncRNA-AFIAR, so that the aim of inhibiting the progress of the AS. Therefore, the invention provides new molecular markers and intervention targets for diagnosing and treating the atherosclerosis and also provides new technical means for treating the atherosclerosis.

The invention relates to long non-coding RNA and application thereof. According to a sequence of the long non-coding RNA, specific qRT-PCR (Quantitative Real-time Polymerase Chain Reaction) primers and probes are designed and synthesized and reagents used for esophageal carcinoma auxiliary diagnosis or curative effect prediction are prepared. The qRT-PCR reagents are utilized for detecting the expression level of the long non-coding RNA in specimens of esophageal carcinoma clinical cases and a substantial decrease of the long non-coding RNS expression is found in esophageal carcinoma. The long non-coding RNA can be applied to preparing reagents used for esophageal carcinoma auxiliary diagnosis, curative effect prediction or prognosis judgment.

The invention belongs to the field of gene engineering, and particularly relates to application of LINC00961 to prediction of non-small-cell lung cancer (NSCLC) prognosis and treatment of target spot medicine. In the NSCLC, down-regulation of the LINC00961 is closely related to clinical stages and tumor sizes, and is closely related to patient prognosis at the same time. The invasion, migration and the like of NSCLC cells are influenced by changing expression of the LINC00961, so that the LINC00961 expression is enhanced, and the invasion and migration of the NSCLC cells can be restrained.

The invention provides a kit applied to embryonic development quality evaluation and a use method. The kit is a biomarker detection reagent used for determining different expression levels of a sperm long non-coding RNA molecule LA16c390E6.5, and the embryonic development quality is evaluated by the expression levels of the LA16c390E6.5; and a gene sequence of the LA16c390E6.5 is shown as SEQ ID No. 1. By clinically utilizing sperm molecular marker long non-coding RNA molecule LA16c390E6.5, the embryonic development potency can be accurately predicted, and guiding significance is provided for curative effect detection and assisted reproduction manner selection.

The invention belongs to technical field of genes, and relates to a long non-coding RNA AY927503 and application thereof. It is proved through experiments that the long non-coding RNA AY927503 can adjust migration of human hepatocellular carcinoma cells, sulfatide can adjust migration of the human hepatocellular carcinoma cells through the long non-coding RNA AY927503, express of integrin alpha V can be adjusted, and the long non-coding RNA AY927503 can adjust migration of the cells through the integrin alpha V; it is proved through experiments that the long non-coding RNA AY927503 is mainly located in cytoplasm and also exists in cell nuclei, the long non-coding RNA AY927503 can adjust the activity of a promoter of the integrin alpha V, and the long non-coding RNA AY927503 is not combined with a transcription factor on the promoter of the integrin alpha V but is directly combined with the promoter of the integrin alpha V. According to the long non-coding RNA AY927503 and the application thereof in gene control, the long non-coding RNA AY927503 can be directly combined with the promoter of the integrin alpha V, adjust the transcriptional activity of the integrin alpha V and then influence the behavior of the cells; the long non-coding RNA AY927503 can be used for preparing a target molecule of the human hepatocellular carcinoma cells.

The invention relates to the technical field of gene engineering, and relates to a long non-coding RNA ENST00000509938.1, and a kit and an application thereof. The long non-coding RNA and a preparation or a diagnostic agent or a drug or the kit and the application thereof are provided; a gene sequence of the long non-coding RNA has a sequence as shown in SEQ ID No:1. Compared with the blood content of health people, the long non-coding RNA ENST00000509938.1 is significantly highly expressed in blood of patients with acute myocardial infarction. The long non-coding RNA ENST00000509938.1 can further enrich researches on a pathogenesis of acute myocardial infarction, and also provides new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction.

The invention discloses a method for SNP locus predicting and influencing the biological function of long non-coding RNA. The method firstly establishes the recognition and significance evaluation method of the specific motif sequence which can be identified by the RNA binding protein contained in the long non-coding RNA, and then evaluates the influence caused by the SNP locus in the specific sequences based on the method. By using the method, SNP locus with important influence on the biological function of the long non-coding RNA can be found, reliable functional research leads are providedfor experimental personnel, and guidance is also provided for clinical application of long non-coding RNA.

The invention relates to esophageal carcinoma-related long non-coding RNA and application thereof. Based on the sequence of the long non-coding RNA, specific qRT-PCR (Quantitative Real-time Polymerase Chain Reaction) primers and probes are designed and synthesized and reagents used for esophageal carcinoma auxiliary diagnosis or curative effect prediction are prepared. The qRT-PCR reagents are utilized for detecting the expression level of the long non-coding RNA in specimens of esophageal carcinoma clinical cases and a substantial decrease of the long non-coding RNS expression is found in esophageal carcinoma. The esophageal carcinoma-related long non-coding RNA can be applied to preparing reagents used for esophageal carcinoma auxiliary diagnosis, curative effect prediction or prognosis judgment.

The invention discloses a detection kit and an application of a novel molecular marker IncRNA (long non-coding RNA) AB007962 for gastric cancer prognosis and provides the molecular marker IncRNA AB007962 with down-regulated expression in the tissue of patients with gastric cancer. Prognosis of patients with low IncRNA AB007962 expression with the Lauren type being intestinal type is poorer than that of patients with high IncRNA AB007962 expression, when the IncRNA AB007962 expression is applied to prognosis prediction of patients with gastric cancer with the Lauren type being intestinal type, powerful molecular biological foundation can be provided for prognosis of the patients, and the detection kit and the application have great clinical meaning and broad application prospects.